Genmab A/S (NASDAQ:GMAB) Price Target Raised to $51.00 at HC Wainwright

Genmab A/S (NASDAQ:GMAB – Get Rating) had its price objective upped by HC Wainwright from $47.00 to $51.00 in a report issued on Monday, The Fly reports. HC Wainwright also issued estimates for Genmab A/S’s FY2023 earnings at $0.83 EPS, Q2 2024 earnings at $0.25 EPS, Q3 2024 earnings at $0.25 EPS, Q4 2024 earnings at $0.24 EPS and FY2024 earnings at $0.83 EPS.

Several other analysts have also recently commented on the company. Danske upgraded Genmab A/S from a hold rating to a buy rating in a report on Thursday, February 23rd. SVB Leerink upped their target price on Genmab A/S from $33.00 to $36.00 and gave the company a market perform rating in a report on Monday, February 6th. Finally, Morgan Stanley assumed coverage on Genmab A/S in a report on Friday, May 12th. They set an underweight rating on the stock. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Genmab A/S currently has a consensus rating of Hold and a consensus target price of $632.62.

Genmab A/S Stock Down 0.4 %

GMAB stock opened at $40.53 on Monday. The company has a market cap of $26.73 billion, a PE ratio of 36.51, a price-to-earnings-growth ratio of 2.08 and a beta of 0.96. The business has a 50-day simple moving average of $39.79 and a 200 day simple moving average of $40.58. Genmab A/S has a 52 week low of $26.19 and a 52 week high of $47.50.

Genmab A/S (NASDAQ:GMAB – Get Rating) last released its quarterly earnings data on Wednesday, February 22nd. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.35 by ($0.23). Genmab A/S had a net margin of 34.34% and a return on equity of 19.67%. The firm had revenue of $717.54 million during the quarter, compared to analyst estimates of $634.17 million. On average, analysts anticipate that Genmab A/S will post 0.99 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Creative Planning purchased a new position in shares of Genmab A/S during the third quarter worth about $395,000. First Trust Advisors LP purchased a new position in shares of Genmab A/S during the third quarter worth about $41,496,000. Schechter Investment Advisors LLC grew its holdings in shares of Genmab A/S by 20.4% during the third quarter. Schechter Investment Advisors LLC now owns 8,166 shares of the company’s stock worth $262,000 after purchasing an additional 1,381 shares in the last quarter. National Bank of Canada FI lifted its position in Genmab A/S by 611.1% in the 4th quarter. National Bank of Canada FI now owns 2,119 shares of the company’s stock worth $90,000 after buying an additional 1,821 shares during the last quarter. Finally, Yorktown Management & Research Co Inc lifted its position in Genmab A/S by 64.4% in the 4th quarter. Yorktown Management & Research Co Inc now owns 16,600 shares of the company’s stock worth $704,000 after buying an additional 6,500 shares during the last quarter. Hedge funds and other institutional investors own 6.73% of the company’s stock.

Genmab A/S Company Profile

(Get Rating)

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia.